Macquarie analyst Zhiwei Foo maintains Sea (NYSE:SE) with a Outperform and lowers the price target from $435 to $285.
Seres Therapeutics Highlights Presentation Of Late-Breaking Phase 3 Data On Its SER-109 In Recurrent C. Difficile Infection At American College Of Gastroenterology Meeting Oct. 26 At 6:25 p.m. EDT
– Study shows that SER-109 reduced the risk of recurrent C. difficile infection in patients with risk factors for recurrence, including acid-reducing medications –
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres
